Medications Primarily Metabolized by the Liver
The vast majority of lipophilic medications undergo hepatic metabolism, with cytochrome P450 enzymes (particularly CYP3A4, CYP2C8, CYP2C9, CYP2C19, and CYP2D6) being responsible for approximately 80% of oxidative drug metabolism and nearly 50% of overall drug elimination. 1
Major Drug Classes and Specific Hepatically Metabolized Medications
Hepatitis C Direct-Acting Antivirals
- Paritaprevir: Primarily metabolized by CYP3A4 2
- Dasabuvir: Primarily metabolized by CYP2C8 2, 3
- Ombitasvir: Undergoes hydrolysis followed by oxidative metabolism 3
- Simeprevir: Primarily undergoes oxidative metabolism via hepatic CYP3A system with biliary excretion 2
Immunosuppressants
- Tacrolimus: Extensively metabolized by hepatic and intestinal CYP3A4 4, 5
- Cyclosporine: Extensively metabolized by hepatic and intestinal CYP3A4 4, 5
- Sirolimus: Metabolized via CYP3A4 and P-glycoprotein pathways 5
- Azathioprine: Undergoes hepatic metabolism 5
Statins (Variable Hepatic Dependence)
- Simvastatin: Extensively metabolized by CYP3A4 4
- Lovastatin: Extensively metabolized by CYP3A4 4
- Atorvastatin: Metabolized by CYP3A4 4
- Fluvastatin: Metabolized by CYP2C9 4
Cardiovascular Medications
- Ivabradine: Extensively metabolized by hepatic and intestinal CYP3A4 4
- Carvedilol: Metabolized by cytochrome P-450 2D6 5
- Digoxin: Requires dose reduction based on hepatic function 6
Antiepileptic Drugs
- Valproic acid: Undergoes extensive hepatic metabolism 7
- Phenytoin: Undergoes extensive hepatic metabolism 7
- Felbamate: Undergoes extensive hepatic metabolism 7
- Carbamazepine: Hepatically metabolized 2
- Phenobarbital: Hepatically metabolized 2
Analgesics
- Opioids: Require dose reduction when hepatic function is impaired 6
Psychotropic Medications
Most psychotropic drugs undergo extensive hepatic metabolism, particularly those with high first-pass metabolism and high protein binding 8
Key Metabolic Pathways
Phase I Metabolism (Cytochrome P450 System)
The liver contains the highest concentration of CYP enzymes, with CYP3A4 being the most abundant and clinically relevant isoform. Drugs extensively metabolized by CYP3A4 are particularly vulnerable to drug-drug interactions and require careful monitoring in hepatic impairment 2, 1.
First-Pass Metabolism
Lipophilic drugs with extensive first-pass metabolism require much larger oral doses than intravenous doses to achieve equivalent plasma concentrations 9. The liver and intestinal wall are the primary sites where this occurs, with enzyme activity, plasma protein binding, and gastrointestinal motility being major determinants 9.
Clinical Implications in Hepatic Impairment
Contraindications in Severe Hepatic Impairment (Child-Pugh C)
Dose Adjustments Required
In moderate hepatic impairment (Child-Pugh B), paritaprevir AUC increases 9.5-fold, while dasabuvir increases 3.3-fold 2. However, no dose adjustment is typically required for mild impairment (Child-Pugh A) 2, 3.
Drugs Requiring Caution
- Methotrexate: Reduce dose when hepatic function is impaired 6
- Cisplatin: Avoid in severe hepatic impairment 6
- Beta-blockers: Reduce dose by 50% in advanced disease 6
Critical Drug-Drug Interactions
Ritonavir, a strong CYP3A4 inhibitor, can markedly increase plasma concentrations of drugs metabolized by this enzyme, leading to serious adverse events 2. Contraindicated combinations include:
- Alfuzosin, amiodarone, ergot derivatives
- Lovastatin, simvastatin, atorvastatin
- Oral midazolam, triazolam
- Carbamazepine, phenytoin, phenobarbital, rifampicin 2
Enzyme inducers (carbamazepine, phenytoin, phenobarbital, rifampin, St. John's Wort) can significantly decrease levels of hepatically metabolized immunosuppressants 5, potentially leading to therapeutic failure or organ rejection.
Safer Alternatives in Hepatic Disease
For antiepileptic therapy in liver disease, levetiracetam, lacosamide, topiramate, gabapentin, and pregabalin should be used as first-line therapy as they have minimal or no hepatic metabolism 7.